

Lawrence Berkeley National Laboratory

Lawrence Berkeley National Laboratory

Title

Quis custodiet ipsos custodies: who watches the watchmen?

Permalink

<https://escholarship.org/uc/item/85s5b6fj>

Author

Ghajar, Cyrus M.

Publication Date

2009-08-21

Commentary:

Quis custodiet ipsos custodiet: Who watches the watchmen?

Cyrus M. Ghajar¹, Roland Meier¹, and Mina J. Bissell^{1*}

¹Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

The work from MJB's laboratory is supported by grants from the U.S. Department of Energy, OBER Office of Biological and Environmental Research (DE-AC02-05CH11231), a Distinguished Fellow Award and Low Dose Radiation Program from the Office of Health and Environmental Research, Health Effects Division, (03-76SF00098); by National Cancer Institute awards R01CA064786, R01CA057621, U54CA126552 and U54CA112970; and by the U.S. Department of Defense (W81XWH0810736) and (W81XWH0510338). CMG is supported by a Glenn T. Seaborg Postdoctoral Fellowship from Lawrence Berkeley National Laboratory. RM is supported by a Swiss National Foundation fellowship (PBZHB-121019) and by the Claudia von Schilling Foundation for Breast Cancer Research.

*To whom correspondence should be addressed:

Life Sciences Division

Lawrence Berkeley National Laboratory

1 Cyclotron Road, Berkeley, CA 94720-8206, USA

Phone: 510.486.4365

Fax: 510.486.5586

Email: MJBissell@lbl.gov

Should this be said again? No cell is an island and in tissue-specificity and cancer, context is supreme.

Decades ago, seminal recombination experiments illustrated the dominant role of mammary mesenchyme in directing epithelial development ¹⁻³, and strongly suggested that the microenvironment plays a significant role also in the manifestation of carcinoma. More direct evidence for such functions came from a study demonstrating that an unadulterated microenvironment can suppress the malignant phenotype and re-direct tumor cells to give rise to normally functioning tissues and indeed healthy mice ⁴. One may wonder why such a stunning finding did not convince the scientific community to pay more attention to the role of context. The answers are complex, not the least of which is that concomitantly with this finding, the roles of oncogenes and mutations were being discovered. That excitement carried the day, specially because no one subsequently determined whether or not these mice generated from malignant cells contained tumorigenic mutations, and no new group reproduced the work. The following decade saw the discovery that even potent oncogenes could be ruled by context ⁵, and another couple of decades later it was shown that similar reprogramming of metastatic melanoma by an embryonic microenvironment was possible ⁶. There are many more examples which are not as clear cut, but are nevertheless compelling. The extensive literature of two-stage carcinogenesis, namely initiation and progression, indeed clearly indicates that “initiation” and DNA damage alone are not sufficient to allow carcinogenesis.

Implicit in these findings is: once a tumor or an oncogene, not always a tumor or an oncogene. A renewed focus on the tumor microenvironment as a therapeutic target ⁷ has also led to the recognition that markers within the microenvironment could have predictive power. Two recently published reports identifying ‘stromal signatures’ in breast cancer patients prognostic

for patient survival⁸ and predictive of response to chemotherapeutic treatment⁹ provide proof of this concept. In the current issue of *The American Journal of Pathology*, two independent studies^{10,11} identify a novel stromal marker, caveolin (Cav)-1, which predicts clinical outcome of breast cancer patients irrespective of its expression in tumor epithelium.

Cav-1 is a scaffolding protein essential to the structure of caveolae, “little caves” or invaginations in cellular plasma membranes¹². Cav-1 recruits and arranges lipids and proteins to these membrane sites to function in endocytosis and signal transduction¹². The observation that Cav-1 expression is attenuated in oncogenically transformed cells¹³ led to exploration of whether Cav-1 loss in mammary epithelium was causative. Although mechanistic data suggested that Cav-1 null mice exhibited aberrant epithelial growth¹⁴, and that forcing Cav-1 expression in breast cancer cell lines inhibited growth and metastases in xenograft models¹⁵, a clinical link proved elusive. However, MMTV-PyMT tumors transplanted into the fat pads of Cav-1 knockout mice displayed significantly enhanced growth (vs. wild-type mice)¹⁴, motivating investigation of whether stromal Cav-1 expression correlates with human breast cancer patient survival.

This is precisely what Sloan et al. and Witkiewicz, Dasgupta, et al. demonstrate in this issue of *AJP*. Using tissue microarray data in conjunction with breast tumor sections and extensive patient survival data, Sloan et al. demonstrate that strong stromal Cav-1 expression is associated with smaller breast tumor size and grade, and is highly predictive of increased survival (Fig. 1). Patients with positive expression of stromal Cav-1 had a 91% ten year survival rate, vs. a 43% survival rate for patients lacking stromal Cav-1 expression. Importantly, there was no correlation between Cav-1 expression in the tumor epithelium and clinical outcome in either tissue arrays or tumor sections¹⁰.

Witkiewicz, Dasgupta, and colleagues independently investigated the clinical significance of stromal Cav-1 expression in a breast tumor tissue microarray. The presence of stromal Cav-1 was strongly associated with tumor size, local spread to lymph nodes, and progression-free survival in Tamoxifen-treated and –untreated patients. Again, tumor Cav-1 expression did not correlate with either of the described metrics ¹¹. Strikingly, both studies found that stromal Cav-1 expression predicted patient survival independent of estrogen receptor (ER), progesterone receptor (PR), or HER2 status ^{10, 11}. Results from these two clinical studies suggest that stromal Cav-1 expression may be a new independent prognostic factor for long-term survival and disease recurrence for breast cancer patients, and the Tamoxifen data suggest that expression of this stromal marker may also predict resistance to treatment.

As with any exciting study, intriguing data raise a number of questions which sow the soil for future studies. Principle amongst these questions is whether Cav-1 is a surrogate or a functional biomarker (summarized in Figure 2):

An argument for Cav-1 being a functional biomarker is that its absence may reflect the physical absence of a Cav-1-expressing cell type (Fig. 2, Scenario 1). While Cav-1 was not expressed in the normal mammary epithelium, both groups observed Cav-1 expression in myoepithelium, endothelium, and fibroblasts ^{10, 11}. Whereas endothelial cells and fibroblasts have demonstrated roles in promoting tumor progression ⁷, myoepithelial cells (MEPs) function as natural tumor suppressors ^{16, 17}. In a three-dimensional model of normal acini, it is the MEPs that confer polarity to luminal cells ¹⁸, and in a xenograft model of breast tumor progression, the presence of normal MEPs prevents conversion of the ductal carcinoma in situ (DCIS) phenotype to invasive ductal carcinoma ¹⁹. This ‘guardian’ function of normal MEPs begins to be lost in situ and MEPs surrounding DCIS are in fact quite abnormal ²⁰. As tumors progress, MEPs are mysteriously

reduced or absent (e.g., in invasive breast tumors) ²¹. Whether MEPs have apoptosed, transdifferentiated, or migrated away is unknown, but it is quite possible that Cav-1 disappears with them. Indeed, enhanced tumor growth and invasion (assessed by tumor cell-positive lymph nodes) observed by Witkiewicz, Dasgupta, et al. to correlate with loss of Cav-1 expression are also noted consequences of MEP loss ²².

If not a surrogate biomarker, Cav-1 may instead be a functional biomarker directly responsible for the tumor suppressor functions of MEPs (Fig. 2, Scenario 2). Carcinoma-associated MEPs lose the ability to deposit an integral component of laminin-rich basement membrane which surrounds breast epithelium, potentially robbing epithelial cells of signals crucial to maintaining their architecture ¹⁸, and secrete chemokines which may foster tumor growth and invasion ²⁰. Loss of Cav-1 expression from MEPs, perhaps induced by factors secreted by either transformed epithelial cells or disrupted stroma, may skew their secretory profile and ultimately promote an invasive phenotype.

Witkiewicz, Dasgupta, et al. make a case for Cav-1 loss exerting its effects in the fibroblast component of the microenvironment (Fig. 2, Scenario 3) ¹¹. This group has recently shown that loss of Cav-1 induces a carcinoma-associated fibroblast (CAF) phenotype ²³, which actively participates in tumor progression ^{24, 25}. Loss of Cav-1 expression may directly mediate transition to the CAF phenotype and promote tumor growth by either attenuating the activity of a tumor suppressor (e.g., retinoblastoma tumor suppressor ²³), activating TGF- β expression, and/or modulating TGF- β receptor activity ^{26, 27}.

Regardless of which scenario may be operating, it is of interest that neither study positively correlated stromal Cav-1 expression with distant metastases (i.e., M-stage). Further.

the offspring of Cav-1 null mice and Her-2/neu mice (which develop mammary-specific tumors) established by Sloan et al.¹⁰ developed tumors faster and required more rapid sacrificing than Her-2/neu counterparts, but did not show increased lung metastases. In light of the survival data, however, the simple question remains: why do patients lacking stromal Cav-1 expression die so fast? It is well accepted that metastatic growths are the cause of breast cancer-related deaths, so determining whether lack of stromal Cav-1 expression at the primary site mediates escape from tumor dormancy at the secondary site in already established mouse models¹⁴ may yield intriguing results. Elaborating upon such studies by deleting Cav-1 in specific cell types (e.g., MEPs, adipocytes) could reveal whether Cav-1 expression is crucial only within certain cell populations and also pinpoint which cell type(s) to use for interrogation of the molecular mechanisms by which reduced Cav-1 expression enhances tumor growth and invasion.

Given the striking prognostic finding of Cav-1 loss in the tumor microenvironment, a final point of discussion is whether stromal Cav-1 also provides a meaningful therapeutic target. Forced expression of Cav-1 in transformed mammary epithelial cells significantly inhibits their growth¹⁴; thus, exploring the biological functions and molecular regulation of Cav-1 in developing mammary stroma as well as in normal adult mammary stroma may further motivate the development of strategies to enhance tissue specific Cav-1 expression in breast cancer patients. For now, the two studies presented in this issue of AJP provide additional validation that the microenvironment is an important and potentially powerful source of clinical information to predict patient outcome, and demonstrate specifically that stromal Cav-1 may be a valuable clinical marker. Determining whether stromal Cav-1 functions to directly suppress tumor growth and the factors which regulate its expression may also reveal novel therapeutic avenues and help unveil who is watching the vigilant watchman.

Acknowledgements.

We are grateful to Jamie L. Inman for critically reading this commentary and providing helpful suggestions.

References.

1. Cunha GR, Young P, Christov K, Guzman R, Nandi S, Talamantes F, Thordarson G: Mammary phenotypic expression induced in epidermal cells by embryonic mammary mesenchyme, *Acta Anat (Basel)* 1995, 152:195-204
2. Propper A, Gomot L: Control of chick epidermis differentiation by rabbit mammary mesenchyme, *Experientia* 1973, 29:1543-1544
3. Sakakura T, Nishizuka Y, Dawe CJ: Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentiation in mouse mammary gland, *Science* 1976, 194:1439-1441
4. Mintz B, Illmensee K: Normal genetically mosaic mice produced from malignant teratocarcinoma cells, *Proc Natl Acad Sci U S A* 1975, 72:3585-3589
5. Dolberg DS, Bissell MJ: Inability of Rous sarcoma virus to cause sarcomas in the avian embryo, *Nature* 1984, 309:552-556
6. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, Margaryan NV, Seftor EA, Seftor RE, Hendrix MJ: Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment, *Proc Natl Acad Sci U S A* 2006, 103:3752-3757
7. Bissell MJ, Radisky D: Putting tumours in context, *Nat Rev Cancer* 2001, 1:46-54
8. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene expression predicts clinical outcome in breast cancer, *Nat Med* 2008, 14:518-527
9. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J, Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer, *Nat Med* 2009, 15:68-74

10. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, Fanelli MA, Cuello-Carrion FD, Gago FE, Anderson RL: Stromal cell expression of caveolin-1 predicts outcome in breast cancer, *The American Journal of Pathology* 2009, 174:
11. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP: An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers, *The American Journal of Pathology* 2009, 174:
12. Hnasko R, Lisanti MP: The biology of caveolae: lessons from caveolin knockout mice and implications for human disease, *Mol Interv* 2003, 3:445-464
13. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells, *Proc Natl Acad Sci U S A* 1995, 92:1381-1385
14. Williams TM, Sotgia F, Lee H, Hassan G, Di Vizio D, Bonuccelli G, Capozza F, Mercier I, Rui H, Pestell RG, Lisanti MP: Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells, *Am J Pathol* 2006, 169:1784-1801
15. Sloan EK, Stanley KL, Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis, *Oncogene* 2004, 23:7893-7897
16. Barsky SH, Karlin NJ: Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression, *J Mammary Gland Biol Neoplasia* 2005, 10:249-260
17. Adriance MC, Inman JL, Petersen OW, Bissell MJ: Myoepithelial cells: good fences make good neighbors, *Breast Cancer Res* 2005, 7:190-197

18. Gudjonsson T, Ronnov-Jessen L, Villadsen R, Rank F, Bissell MJ, Petersen OW: Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition, *J Cell Sci* 2002, 115:39-50
19. Hu M, Yao J, Carroll DK, Weremowicz S, Chen H, Carrasco D, Richardson A, Violette S, Nikolskaya T, Nikolsky Y, Bauerlein EL, Hahn WC, Gelman RS, Allred C, Bissell MJ, Schnitt S, Polyak K: Regulation of in situ to invasive breast carcinoma transition, *Cancer Cell* 2008, 13:394-406
20. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, Schnitt S, Sellers WR, Polyak K: Molecular characterization of the tumor microenvironment in breast cancer, *Cancer Cell* 2004, 6:17-32
21. Gusterson BA, Warburton MJ, Mitchell D, Ellison M, Neville AM, Rudland PS: Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases, *Cancer Res* 1982, 42:4763-4770
22. Man YG, Tai L, Barner R, Vang R, Saenger JS, Shekitka KM, Bratthauer GL, Wheeler DT, Liang CY, Vinh TN, Strauss BL: Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion, *Breast Cancer Res* 2003, 5:R231-241
23. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, Lisanti MP: Caveolin-1^{-/-} null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts, *Am J Pathol* 2009, 174:746-761

24. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium, *Cancer Res* 1999, 59:5002-5011
25. Orimo A, Gupta PB, SgROI DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, *Cell* 2005, 121:335-348
26. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL: TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia, *Science* 2004, 303:848-851
27. Radisky DC, Bissell MJ: Cancer. Respect thy neighbor!, *Science* 2004, 303:775-777

Figure Legend.

Figure 1: Stromal Caveolin-1 (Cav-1) expression predicts breast cancer patient outcome. In this issue of *The American Journal of Pathology*, Sloan et al. and Witkiewicz, Dasgupta et al. show that an absence of staining for the structural protein Cav-1 in the breast tumor microenvironment (reflected by reduced shading of myoepithelial cells, blue, and fibroblasts, green) is predictive of poor clinical outcome for breast cancer patients. Importantly, Cav-1 expression in the tumor epithelium does not correlate with patient outcome.

Figure 2: Three possible scenarios by which Cav-1 loss mediates tumor invasion in the breast tumor microenvironment. *Left:* Schematic view of a cross-sectioned normal mammary duct. An inner layer of luminal epithelial cells (red) is surrounded basally by myoepithelial cells (blue) and basement membrane (black). *Right:* Loss of Cav-1 could coincide with or result in 3 distinct scenarios. **Scenario 1:** Absence of Cav-1 coincides with loss of myoepithelial cells (MEPs). MEPs are more often found in benign breast lesions than in advanced carcinomas²¹. Since Cav-1 is expressed by MEPs, MEP loss would be reflected by an absence of Cav-1 staining. **Scenario 2:** Loss of Cav-1 mediates loss of MEP function, resulting in invasive ductal carcinoma. Cancer-associated MEPs behave distinctly from normal MEPs, which function as tumor suppressors¹⁶. Loss of Cav-1 may directly alter the secretion profile of MEPs such that they are unable to regulate architecture, ultimately resulting in tumor invasion. **Scenario 3:** Loss of Cav-1 induces differentiation of surrounding fibroblasts to a carcinoma-associated fibroblast (CAF) phenotype. Normal breast fibroblasts express Cav-1^{10, 11}. Loss of Cav-1 in fibroblasts could directly initiate their transition to CAFs (green), which secrete a variety of factors to promote invasion and possibly inhibit the production of Cav-1 in other cell types (e.g., MEPs), thereby further promoting invasion by the means described in Scenario 2.

FIGURE 1: Stromal Caveolin-1 (Cav-1) expression predicts breast cancer patient outcome.




FIGURE 2: Three possible scenarios by which Cav-1 loss mediates tumor invasion in the breast tumor microenvironment.

